Amgen stock target raised to 542 dollars by Piper Sandler
Published on 11/20/2026 at 12:55 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSPiper Sandler broadens Amgen outlook
- Piper Sandler linked its revised view to dazodalibep, Imdelltra and Amgen's wider pipeline.
- The analyst cited growth in the base business as a potential offset to future loss-of-exclusivity exposure.
- The updated assessment adds a fresh analyst catalyst for investors following Amgen's late-stage development portfolio.
Piper Sandler raised its price target for Amgen on Thursday, November 19, while keeping an Overweight rating on the shares, according to Markets Insider. The firm lifted the target from 457 US dollars to 542 US dollars in a post-third-quarter model update.
Markets Insider reported that the revised model reflects a potential contribution from dazodalibep in patients with Sjogren's disease who have a moderate-to-severe systemic disease burden. It also incorporates Imdelltra as maintenance therapy for patients with first-line extensive-stage small cell lung cancer.
Pipeline opportunities drive revision
Piper Sandler said the two opportunities could each support further value creation for Amgen. The firm also pointed to the depth of the company's pipeline and possible label expansions as factors that could support a higher valuation multiple.
The analyst's assessment places the development portfolio alongside Amgen's established commercial base. Piper Sandler expects the core business to continue generating growth that can help offset the future impact of products losing market exclusivity. That view makes the target revision relevant beyond a single clinical program: it reflects an attempt to balance pipeline potential with longer-term patent and competition risks.
For investors, the update adds a new analyst view around two separate drivers. Dazodalibep represents a potential expansion of Amgen's autoimmune franchise, while Imdelltra offers a route to broader use of an already approved oncology treatment. The commercial outcome for both programs will depend on regulatory progress, adoption and the ability to translate clinical or label-expansion opportunities into revenue.
Amgen stock at Lang & Schwarz
Amgen stock traded at 404.75 euros on Lang & Schwarz at 12:47 CET on Friday, November 20, 2026.
Amgen stock facts
- Company: Amgen Inc.
- ISIN: US0311621009
- Ticker: AMGN
- Lang & Schwarz quote: 404.75 euros on Friday, November 20, 2026, at 12:47 CET
- Piper Sandler target: 542 US dollars
- Rating: Overweight
The revision gives Amgen's shares another catalyst tied to late-stage development and product expansion. It also leaves investors focused on execution: pipeline progress, regulatory milestones and the durability of the existing portfolio will determine whether the opportunities described by Piper Sandler translate into the growth assumed in its updated model.
Amgen stock is part of the broader US equity market represented by the S&P 500.
